Biopharmaceutics Risk Assessment to Guide Dissolution Method Development for Solid Oral Dosage Forms
24:45
Panel Discussion
35:21
Decrease RTR, IR, and CR Due to Dissolution Deficiencies (21of28) GDF – Apr. 3-4, 2019
15:23
Dissolution Method Development for Generic Drugs (24/28) Generic Drugs Forum 2017
1:57:16
M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance
2:25:28
Navigating First ICH Generic Drug Draft Guideline M13A Bioequivalence for IR Solid Oral Dosage Forms
1:56:59
Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA
19:19
Biopharmaceutics Classification System Class 3 Waiver
1:00:00